A Phase 1, First-in-Human Study of MEN2312, a KAT6 inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer
MEN2312-01
Phase 1 other active
Quick answer
A Phase 1, First-in-Human Study of MEN2312, a KAT6 inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer for Advanced ER+/HER2- Breast Cancer is a Phase 1 program (other) at Stemline Therapeutics B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Stemline Therapeutics B.V.
- Indication
- Advanced ER+/HER2- Breast Cancer
- Phase
- Phase 1
- Modality
- other
- Status
- active